Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Novartis is rolling out new data that build on its case for the company’s blockbuster hopeful RTH258, an investigational therapy that might carve away a considerable chunk of Regeneron’s $5 billion Eylea franchise if approved.
The new data, which came from a secondary analysis of two Phase III trials, show a compelling case for the drug as a treatment for wet age-related macular degeneration. The drug already showed impressive success in those trials last fall, when it performed well in a head-to-head comparison to Eylea. Simply put, Novartis’ CEO Vas Narasimhan said the drug was “consistently superior” to its Regeneron rival.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.